[Enhanced immune functions and antitumor activity of fibroblast-mediated interleukin-2 gene therapy]. 1995

X T Cao, and W P Zhang, and Q Tao
Department of Immunology, Second Military Medical University, Shanghai.

The aim of the present study was to establish fibroblastmediated IL-2 gene therapy and to observe its antitumor effect in the mouse tumor model. The IL-2 gene-transfected fibroblasts (NIH3T3-IL-2+) secreting high level of IL-2 were encapsulated with collagen and then implanted i.p. into mice. Certain level of IL-2 could be detected in murine serum for some periods, and the splenic proliferation, NK and LAK activities, cytokine production (IFN-v, TNF, IL-2) were enhanced significantly. It was of great importance that the high endogenous LAK activity was induced. The significant therapeutic effect of i.p. implantation of NIH3T3-IL-2+ on ascitic liver carcinoma-bearing mice was observed. The better therapeutic results could be achieved. NIH3T3-IL-2+ cells were i.p. implanted in combination with i.p. injection of LAK cells. These results demonstrated that fibroblast--mediated IL-2 gene therapy has potent antitumor effect via augmentation of immune functions and the antitumor effect will be more obvious when IL-2 gene therapy is used along with the adoptive transfer of LAK cells.

UI MeSH Term Description Entries
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008114 Liver Neoplasms, Experimental Experimentally induced tumors of the LIVER. Hepatoma, Experimental,Hepatoma, Morris,Hepatoma, Novikoff,Experimental Hepatoma,Experimental Hepatomas,Experimental Liver Neoplasms,Hepatomas, Experimental,Neoplasms, Experimental Liver,Experimental Liver Neoplasm,Liver Neoplasm, Experimental,Morris Hepatoma,Novikoff Hepatoma
D008297 Male Males
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014162 Transfection The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES. Transfections
D015316 Genetic Therapy Techniques and strategies which include the use of coding sequences and other conventional or radical means to transform or modify cells for the purpose of treating or reversing disease conditions. Gene Therapy,Somatic Gene Therapy,DNA Therapy,Gene Therapy, Somatic,Genetic Therapy, Gametic,Genetic Therapy, Somatic,Therapy, DNA,Therapy, Gene,Therapy, Somatic Gene,Gametic Genetic Therapies,Gametic Genetic Therapy,Genetic Therapies,Genetic Therapies, Gametic,Genetic Therapies, Somatic,Somatic Genetic Therapies,Somatic Genetic Therapy,Therapies, Gametic Genetic,Therapies, Genetic,Therapies, Somatic Genetic,Therapy, Gametic Genetic,Therapy, Genetic,Therapy, Somatic Genetic
D015979 Killer Cells, Lymphokine-Activated Cytolytic lymphocytes with the unique capacity of killing natural killer (NK)-resistant fresh tumor cells. They are INTERLEUKIN-2-activated NK cells that have no MAJOR HISTOCOMPATIBILITY COMPLEX restriction or need for antigen stimulation. LAK cells are used for ADOPTIVE IMMUNOTHERAPY in cancer patients. LAK Cells,Lymphokine-Activated Killer Cells,Cell, LAK,Cell, Lymphokine-Activated Killer,Cells, LAK,Cells, Lymphokine-Activated Killer,Killer Cell, Lymphokine-Activated,Killer Cells, Lymphokine Activated,LAK Cell,Lymphokine Activated Killer Cells,Lymphokine-Activated Killer Cell

Related Publications

X T Cao, and W P Zhang, and Q Tao
January 2003, Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition,
X T Cao, and W P Zhang, and Q Tao
September 1999, American journal of respiratory cell and molecular biology,
X T Cao, and W P Zhang, and Q Tao
August 2003, Gene therapy,
X T Cao, and W P Zhang, and Q Tao
July 2017, Journal of controlled release : official journal of the Controlled Release Society,
X T Cao, and W P Zhang, and Q Tao
March 1998, Zhonghua zhong liu za zhi [Chinese journal of oncology],
X T Cao, and W P Zhang, and Q Tao
April 1989, Journal of biological response modifiers,
X T Cao, and W P Zhang, and Q Tao
December 1994, The Journal of allergy and clinical immunology,
Copied contents to your clipboard!